Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting

Martina D. Sahre, Lauren Milligan, Rajanikanth Madabushi, Richard A. Graham, Kellie S. Reynolds, Andre Terzic, Jessica Benjamin, Gilbert J. Burckart, Shiew Mei Huang, Robert Schuck, Aliza M. Thompson, Issam Zineh

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with multiple chronic conditions, including more advanced chronic kidney disease (CKD), are often excluded from clinical trials, creating challenges in deriving appropriate dosing information and labeling. This article summarizes the May 7, 2019, US Food and Drug Administration Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting, which solicited expert opinions on how to enroll patients with more advanced CKD into clinical trials as well as the assumptions behind and different approaches of exposure-matching.

Original languageEnglish (US)
JournalClinical pharmacology and therapeutics
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting'. Together they form a unique fingerprint.

Cite this